BIOTECHNOLOGY News & Analysis

Fair value uneffected by suspended early-stage clinical trials.

CSL's Behring division shone but markets were left underwhelmed by the company's guidance for 2025.

Benchmark rebalance in June put pressure on some small-cap managers to get into the sector.

A return to normal has increased the incidence of burns and that means business for the spray-on-skin maker.

Subsectors such as biotechnology, pharmaceuticals and diagnostics feature some globally listed names that are trading at discounts.

And Morningstar analyst Nicolette Quinn has tempered her forecasts for sales of immunoglobulins.

A long road lies ahead as the trial continues, but we are maintaining our fair value estimates for the two healthcare firms, says Morningstar’s...

Fisher & Paykel’s share price has soared as COVID-19 cases rise in Australia, US and Europe, while CSL’s latest acquisition marks...

Morningstar's Karen Andersen explains how environmental, social and governance issues affect Big Pharma and biotech companies.

Spray-on-skin maker Avita has had runaway success on the ASX. And it's not done yet, says Morningstar's Nicolette Quinn.